Small molecule · Inhibitor of proteasome beta 5 subunit (20S proteasome) (PSMB5) · developed by Takeda Pharms Usa
Ixazomib is an orally bioavailable proteasome inhibitor that reversibly binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome, leading to accumulation of misfolded proteins and induction of apoptosis. It is used in combination with lenalidomide and dexamethasone for multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 11, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07881809 | Phase 2 | HIV (Human Immunodeficiency Virus) | Not yet recruiting | TAK |
| NCT02542657 | Phase 1/2 | Myeloma | Completed | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HIV (Human Immunodeficiency Virus)Myeloma
Updated Nov 15, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →